Cabiralizumab
As of the edition of 20 October 2026, Cabiralizumab is an antibody: stopped in 2026; acts on CSF1R.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2026
- Kind
- Antibody
- Registered trials
- 13, 4 stopped early
- Disease areas
- Cancer; Digestive system; Hormones; Bones, joints and muscles; Immune system; Lungs and airways
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
1 company on route A because of this drug.
Companies on route A for this drug
In the product1 company is on route A because of Cabiralizumab.
See the 1 company on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| CSF1R | Macrophage colony-stimulating factor 1 receptor | P07333 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 6 | 5 | 0 | 1 |
| Phase 2 | 7 | 4 | 0 | 3 |
| All trials | 13 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Amgen | Lead sponsor of trials | 2013 to now |
| Bristol Myers Squibb | Lead sponsor of trials | 2017 to now |